Northwest Georgia Oncology Centers - Douglasville

We’re committed to FIGHTING FOR YOU.   The cancer care and treatment experts at Northwest Georgia Oncology Centers, P.C. (NGOC) collaboratively work to provide patients with the most advanced cancer treatment options available in Georgia at nine cancer center locations.  NGOC oncologists are actively involved in cancer research through clinical trials, the treatment of difficult cancer cases and public policy to ensure people in Georgia have access to the best community-based cancer care.   NGOC is a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers.   For more information about NGOC cancer center locations and patient services, visit www.ngoc.com.

Treatment Sites in Georgia

Primary Location

6002 Professional Parkway
Suite 220
Douglasville, GA 30134
678-715-9690 (p)
678-581-7140 (f)
www.ngoc.com

driving directions

Clinical Trials in Georgia

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Cancer Type: Lung Cancer

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Mary Gilley - 770-281-5131


A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Cancer Type: Multiple Myeloma

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type: Multiple Myeloma
Study Coordinator: Mary Gilley - 770-281-5131


A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Mary Gilley - 770-281-5131


A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type: Lung Cancer

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type: Ovarian Cancer

A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM). (KEYNOTE 183)
Cancer Type: Multiple Myeloma

A Phase III, Open-label, Multicenter, Randomzed Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination With Carboplatin + Paclitaxel or MPDL3208A in Combination With Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)
Cancer Type: Lung Cancer

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, GPNMB Over-Expressing, Triple Negative Breast Cancer. (The METRIC Study)
Cancer Type: Breast Cancer
Study Coordinator: Mary Gilley - 770-281-5131


A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Cancer Type: Lymphoma

An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 (T-DM1) Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Treated With the Equivalent T-DM1 Regimen in a Genentech and/or F. Hoffmann-La Roche Ltd.-Sponsored T-DM1 Study
Cancer Type: Breast Cancer
Study Coordinator: Mary Gilley - (770) 281-5131


Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)
Cancer Type: Breast Cancer

Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Cancer Type: Leukemia

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
Cancer Type: Breast Cancer

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1
Cancer Type: Solid Tumor
Study Coordinator: Mary Gilley - 770-281-5131


Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Cancer Type: Solid Tumor
Study Coordinator: Mary Gilley - 770-281-5131


Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex®) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy
Cancer Type: Breast Cancer
Study Coordinator: Mary Gilley - 770-281-5131


Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Cancer Type: Pancreatic Cancer